Stock AnalizWarby Parker Inc. WRBY
Ophthalmic Goods · IPO 2021 · data as of November 13, 2026
Warby Parker Inc. (WRBY) is a healthcare company listed in the US with a market value of about $3.4B. In the twelve months to September 30, 2026 it had revenue of $935M and net income of $7M, a net margin of 0.8%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 457.3, a price to free cash flow of 160.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $935M | $872M | $771M | $670M | $598M | $541M | $394M | $370M |
| Net income | $7M | $2M | -$20M | -$63M | -$110M | -$144M | -$56M | $0 |
| Free cash flow | $21M | $44M | $35M | $7M | -$50M | -$81M | $13M | -$11M |
| EPS (diluted) | $0.06 | $0.01 | $-0.17 | $-0.54 | $-0.96 | $-2.21 | $-1.05 | $-1.10 |
| Net margin | 0.8% | 0.2% | -2.6% | -9.4% | -18.5% | -26.7% | -14.2% | 0.0% |
| ROIC | — | -0.5% | -4.2% | -11.9% | -19.1% | -26.3% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $32.25, 18% above the current price; targets range from $25.00 to $40.00; the consensus rating is “Buy”; expected EPS is $0.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Warby Parker’s P/E ratio?
About 457.3, based on the last twelve months of diluted earnings per share (forward P/E about 48.0).
Is Warby Parker stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Warby Parker pay a dividend?
Not currently.
Is Warby Parker a good stock to buy?
We do not give buy or sell advice. Warby Parker scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.